Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894591 | 0.84 | RAB9A (0.50) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL612840 | 0.83 | TDP1 (0.56) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6122839 | 0.78 | RAB9A (0.50) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL3231459 | 0.75 | TDP1 (0.63) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL11758524 | 0.75 | TDP1 (0.53) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL1896049 | 0.74 | CHRNA7 (0.46) | CYP1A2CYP2C19GRM5 | |
| SCHEMBL10707720 | 0.74 | TDP1 (0.56) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL12709324 | 0.73 | ALDH1A1 (0.45) | MAPTRAB9ASMN1; SMN2MMP2MMP3 | |
| SCHEMBL4351612 | 0.72 | TDP1 (0.66) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6898278 | 0.72 | CHRM2 (0.53) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493571-B1 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-23 | — | — | EP | disclosed |
| US-8633322-B2 | Alkynyl derivatives useful as DPP-1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-21 | — | — | US | disclosed |
| EP-2493571-A1 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011059731-A1 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-19 | — | — | WO | disclosed |
| US-20110105562-A1 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105562-A1 | ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS | DPP4, DPP3, DPP7 | MAPT 2030/4885RAB9A 2507/4885SMN1; SMN2 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.